참고문헌 (38)

1. 1 Kris MG Johnson BE Berry LD Kwiatkowski DJ Iafrate AJ Wistuba II Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs JAMA 2014 311 1998 2006 24846037 

   상세보기

2. 2 Shi Y Au JS Thongprasert S Srinivasan S Tsai CM Khoa MT A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) J Thorac Oncol 2014 9 154 62 24419411 

   상세보기

3. 3 Hsu KH Ho CC Hsia TC Tseng JS Su KY Wu MF Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan PLoS One 2015 10 e0120852 25789627 

   상세보기

4. 4 Kuan FC Kuo LT Chen MC Yang CT Shi CS Teng D Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis Br J Cancer 2015 113 1519 28 26461059 

   상세보기

5. 5 Lee CK Davies L Wu YL Mitsudomi T Inoue A Rosell R Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival J Natl Cancer Inst 2017 109 djw279 

   상세보기

6. 6 Park K Tan EH O’Byrne K Zhang L Boyer M Mok T Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Lancet Oncol 2016 17 577 89 27083334 

   상세보기

7. 7 Wu YL Cheng Y Zhou X Lee KH Nakagawa K Niho S Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Lancet Oncol 2017 18 1454 66 28958502 

   상세보기

8. 8 Soria JC Ohe Y Vansteenkiste J Reungwetwattana T Chewaskulyong B Lee KH Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer N Engl J Med 2018 378 113 25 29151359 

   상세보기

9. 9 Ramalingam SS Vansteenkiste J Planchard D Cho BC Gray JE Ohe Y Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC N Engl J Med 2020 382 41 50 31751012 

   상세보기

10. 10 Ito K Morise M Wakuda K Hataji O Shimokawaji T Takahashi K A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903 ESMO Open 2021 6 100115 33984681 

    상세보기

11. 11 Chen DS Mellman I Oncology meets immunology: the cancer-immunity cycle Immunity 2013 39 1 10 23890059 

    상세보기

12. 12 Stinchcombe TE Janne PA Wang X Bertino EM Weiss J Bzhenova L Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 randomized clinical trial JAMA Oncol 2019 5 1448 55 31393548 

    상세보기

13. 13 Seto T Kato T Nishio M Goto K Atagi S Hosomi Y Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study Lancet Oncol 2014 15 1236 44 25175099 

14. 14 Saito H Fukuhara T Furuya N Watanabe K Sugawara S Iwasawa S Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial Lancet Oncol 2019 20 625 35 30975627 

15. 15 Maemondo M Fukuhara T Saito H Furuya N Watanabe K Sugawara S NEJ026: final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations J Clin Oncol 2020 38 15 Suppl 9506 

16. 16 Nakagawa K Garon EB Seto T Nishio M Ponce Aix S Paz-Ares L Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 2019 20 1655 69 31591063 

    상세보기

17. 17 Zhou Q Wu YL Cheng Y Liu Y Chen G Cui J CTONG 1509: phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC Ann Oncol 2019 30 Suppl 5 v603 

18. 18 Ninomiya T Ishikawa N Inoue K Kubo T Yasugi M Shibayama T Phase 2 study of afatinib alone or combined with bevacizumab in chemonaive patients with advanced non-small-cell lung cancer harboring EGFR mutations: AfaBev-CS study protocol Clin Lung Cancer 2019 20 134 8 30514667 

    상세보기

19. 19 Hsu PC Huang CY Wang CC Kuo SC Chu CH Tung PH The combination of afatinib and bevacizumab in untreated EGFR-mutated advanced lung adenocarcinoma: a multicenter observational study Pharmaceuticals (Basel) 2020 13 331 

    상세보기

20. 20 Wang CC Chiu LC Tung PH Kuo SC Chu CH Huang AC A real-world analysis of patients with untreated metastatic epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma receiving first-line erlotinib and bevacizumab combination therapy Oncol Ther 2021 9 489 503 33990928 

21. 21 Tsai JS Su PL Yang SC Chang CC Lin CY Yen YT EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer: a propensity score matching analysis J Formos Med Assoc 2021 120 1729 39 33865672 

22. 22 Tsai TH Su KY Wu SG Chang YL Luo SC Jan IS RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer Eur Respir J 2012 39 677 84 21719485 

    상세보기

23. 23 Su KY Chen HY Li KC Kuo ML Yang JC Chan WK Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer J Clin Oncol 2012 30 433 40 22215752 

    상세보기

24. 24 Ninomiya T Nogami N Kozuki T Harada D Kubo T Ohashi K A phase I trial of afatinib and bevacizumab in chemonaive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404 Lung Cancer 2018 115 103 8 29290249 

25. 25 Ninomiya T Nogami N Kozuki T Harada D Kubo T Ohashi K Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404 Ann Oncol 2019 30 Suppl 5 v626 

26. 26 Ko R Shukuya T Imamura CK Tokito T Shimada N Koyama R Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations Transl Lung Cancer Res 2021 10 183 92 33569303 

    상세보기

27. 27 Harrison PT Vyse S Huang PH Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer Semin Cancer Biol 2020 61 167 79 31562956 

    상세보기

28. 28 Hong S Gao F Fu S Wang Y Fang W Huang Y Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer JAMA Oncol 2018 4 739 42 29596544 

    상세보기

29. 29 Jiao XD He X Qin BD Liu K Wu Y Liu J The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base J Thorac Dis 2019 11 4507 15 31903239 

    상세보기

30. 30 Kim Y Lee SH Ahn JS Ahn MJ Park K Sun JM Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib Cancer Res Treat 2019 51 502 9 29898592 

    상세보기

31. 31 Yu HA Paz-Ares LG Yang JC Lee KH Garrido P Park K Phase I study of the efficacy and safety of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant non-small cell lung cancer Clin Cancer Res 2021 27 992 1002 33046516 

    상세보기

32. 32 Akamatsu H Toi Y Hayashi H Fujimoto D Tachihara M Furuya N Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor: West Japan Oncology Group 8715L phase 2 randomized clinical trial JAMA Oncol 2021 7 386 94 33410885 

33. 33 Yu HA Schoenfeld AJ Makhnin A Kim R Rizvi H Tsui D Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1/2 single-group open-label trial JAMA Oncol 2020 6 1048 54 32463456 

    상세보기

34. 34 Yu HA Arcila ME Rekhtman N Sima CS Zakowski MF Pao W Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 2013 19 2240 7 23470965 

    상세보기

35. 35 Huang YH Hsu KH Tseng JS Chen KC Hsu CH Su KY The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma Cancer Res Treat 2018 50 1294 303 29334606 

    상세보기

36. 36 Hochmair MJ Morabito A Hao D Yang CT Soo RA Yang JC Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study Future Oncol 2020 16 2799 808 32854536 

37. 37 Reck M von Pawel J Zatloukal P Ramlau R Gorbounova V Hirsh V Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer: AVAil J Clin Oncol 2009 27 1227 34 19188680 

    상세보기

38. 38 Mok TS Hsia TC Tsai CM Tsang K Chang GC Chang JW Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial Asia Pac J Clin Oncol 2011 7 Suppl 2 4 12